Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 674101, 10 pages
Research Article

Evaluation of Safety and Protective Effect of Combined Extract of Cissampelos pareira and Anethum graveolens (PM52) against Age-Related Cognitive Impairment

1Neuroscience Program Department of Physiology and Graduate School, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
2Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
3Integrative Complementary Alternative Medicine Research and Development Group, Khon Kaen University, Khon Kaen 40002, Thailand

Received 5 June 2012; Accepted 4 August 2012

Academic Editor: Tibor Wenger

Copyright © 2012 Wipawee Thukham-mee and Jintanaporn Wattanathorn. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The present study aimed to determine acute toxicity, the protective effect, and underlying mechanism of PM52, a combined extract of Cissampelos pareira and Anethum graveolens, against age-related cognitive impairment in animal model of age-related cognitive impairment. PM52 was determined as acute toxicity according to OECD guideline. Male Wistar rats, weighing 180–220 g, were orally given PM52 at doses of 2, 10, and 50 mg/kg at a period of 14 days before and 7 days after the bilateral administration of AF64A via intracerebroventricular route. All animals were assessed according to spatial memory, neuron density, MDA level, the activities of SOD, CAT, GSH-Px, and AChEI effect in hippocampus. It was found that all doses of PM52 could attenuate memory impairment and neurodegeneration in hippocampus. The possible mechanisms might occur via the suppression of AChE and the decreased oxidative stress in hippocampus. Therefore, our data suggest that PM52 may serve as food supplement to protect against age-related cognitive impairment such as mild cognitive impairment (MCI) and early phase of Alzheimer’s disease. However, further researches are still essential.